ADMA Biologics Stock Performance


USD 3.36  0.13  4.02%   

On a scale of 0 to 100, ADMA Biologics holds a performance score of 8. The firm shows a Beta (market volatility) of 2.1391, which signifies a somewhat significant risk relative to the market. Let's try to break down what ADMA Biologics's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ADMA Biologics will likely underperform. Although it is vital to follow ADMA Biologics historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The approach into foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-seven technical indicators for ADMA Biologics, which you can use to evaluate the performance of the firm. Please makes use of ADMA Biologics treynor ratio, downside variance, and the relationship between the total risk alpha and value at risk to make a quick decision on whether ADMA Biologics price patterns will revert.
ADMA Biologics Performance
8 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in ADMA Biologics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady primary indicators, ADMA Biologics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more

ADMA Biologics Price Channel

Begin Period Cash Flow55921152.00
Total Cashflows From Investing Activities-13511258.00

ADMA Biologics Relative Risk vs. Return Landscape

If you would invest  258.00  in ADMA Biologics on September 4, 2022 and sell it today you would earn a total of  78.00  from holding ADMA Biologics or generate 30.23% return on investment over 90 days. ADMA Biologics is currently generating 0.5191% in daily expected returns and assumes 4.8133% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than ADMA Biologics, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Daily Expected Return (%)  
       Risk (%)  
Given the investment horizon of 90 days ADMA Biologics is expected to generate 3.22 times more return on investment than the market. However, the company is 3.22 times more volatile than its market benchmark. It trades about 0.11 of its potential returns per unit of risk. The NYSE Composite is currently generating roughly 0.09 per unit of risk.

ADMA Biologics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for ADMA Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ADMA Biologics, and traders can use it to determine the average amount a ADMA Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.1078

Good Returns
Average Returns
Small ReturnsADMA
Negative Returns
Estimated Market Risk
  actual daily
 41 %
of total potential
Expected Return
  actual daily
 10 %
of total potential
Risk-Adjusted Return
  actual daily
 8 %
of total potential
Based on monthly moving average ADMA Biologics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ADMA Biologics by adding it to a well-diversified portfolio.

About ADMA Biologics Performance

To evaluate ADMA Biologics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when ADMA Biologics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare ADMA Biologics Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand ADMA Biologics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents ADMA Biologics's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Investment(27.98) (30.19) 
Return on Average Assets(29.61) (31.95) 
Return on Average Equity(62.46) (67.39) 
Return on Invested Capital(0.22) (0.24) 
Return on Sales(0.72) (0.78) 

Things to note about ADMA Biologics

Checking the ongoing alerts about ADMA Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ADMA Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

ADMA Biologics Alerts

Equity Alerts and Improvement Suggestions

ADMA Biologics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 80.94 M. Net Loss for the year was (71.65 M) with profit before overhead, payroll, taxes, and interest of 1.17 M.
ADMA Biologics currently holds about 52.42 M in cash with (112.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27.
ADMA Biologics has a frail financial position based on the latest SEC disclosures
Over 80.0% of the company shares are held by institutions such as insurance companies
Latest headline from Institutional investors are ADMA Biologics, Inc.s biggest bettors and were rewarded after last weeks US139m market cap gain - Simply Wall St
Please continue to Trending Equities. You can also try Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for analysis

When running ADMA Biologics price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Is ADMA Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
661.2 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine ADMA Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.